N.J. banned substances policy
This article was originally published in The Tan Sheet
Executive Summary
A student athlete may not "possess, ingest, or otherwise use" the "anabolic steroid" DHEA (dehydroepiandrosterone) or bitter orange (synephrine), under a policy adopted by the New Jersey State Interscholastic Athletic Association (NJSIAA) June 7. Caffeine or guarana - if the concentration in urine exceeds 15 µg/ml - and ephedrine (ephedra or ma huang) are also banned. Additionally prohibited are "substances that are included in the [stimulant or anabolic agent] class by their pharmacological action and/or chemical structure." The official 2006-2007 "NJSIAA Banned-Drug Classes" list notes that "many nutritional/dietary supplements contain NJSIAA banned substances," and concludes in bold type that since FDA "does not strictly regulate" the industry "the use of supplements is at the student-athlete's own risk." The policy is the result of a December 2005 executive order by former Acting Gov. Richard Codey (D). The order was issued following a state report on steroid use and prevention, which was prompted in turn by a New York State Task Force on Life & the Law report released in October (1"The Tan Sheet" Oct. 10, 2005, p. 6)...
You may also be interested in...
NY Proposal To Age-Restrict Creatine Sales Draws CRN Criticism
CRN argues that legislation a New York state assembly member authored to ban sales of supplements to consumers younger than 18 would restrict the sale of the supplements to all consumers.
New York State Authority To Ban Supplements Sought By Task Force
A task force under the New York State Department of Health is advocating that the state health commissioner have the authority to ban the sale of any dietary supplements deemed "unsafe.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.